Cargando…

Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways

Oral cancer is one of the most common cancers in the world. Approximately 90% of oral cancers are subtyped to oral squamous cell carcinoma (OSCC). Despite advances in diagnostic techniques and improvement in treatment modalities, the prognosis remains poor. Therefore, an effective chemotherapy mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Ming-Ju, Lin, Chiao-Wen, Chen, Mu-Kuan, Chien, Su-Yu, Lo, Yu-Sheng, Chuang, Yi-Ching, Hsi, Yi-Ting, Lin, Chia-Chieh, Chen, Jui-Chieh, Yang, Shun-Fa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361207/
https://www.ncbi.nlm.nih.gov/pubmed/28327651
http://dx.doi.org/10.1038/srep45039
_version_ 1782516726715383808
author Hsieh, Ming-Ju
Lin, Chiao-Wen
Chen, Mu-Kuan
Chien, Su-Yu
Lo, Yu-Sheng
Chuang, Yi-Ching
Hsi, Yi-Ting
Lin, Chia-Chieh
Chen, Jui-Chieh
Yang, Shun-Fa
author_facet Hsieh, Ming-Ju
Lin, Chiao-Wen
Chen, Mu-Kuan
Chien, Su-Yu
Lo, Yu-Sheng
Chuang, Yi-Ching
Hsi, Yi-Ting
Lin, Chia-Chieh
Chen, Jui-Chieh
Yang, Shun-Fa
author_sort Hsieh, Ming-Ju
collection PubMed
description Oral cancer is one of the most common cancers in the world. Approximately 90% of oral cancers are subtyped to oral squamous cell carcinoma (OSCC). Despite advances in diagnostic techniques and improvement in treatment modalities, the prognosis remains poor. Therefore, an effective chemotherapy mechanism that enhances tumor sensitivity to chemotherapeutics is urgently needed. Methyl protodioscin (MP) is a furostanol bisglycoside with a wide range of beneficial effects, including anti-inflammatory and anti-cancer properties. The aim of the present study was to determine the antitumor activity of MP on OSCC and its underlying mechanisms. Our results show that treatment of OSCC cells with MP potently inhibited cell viability. Moreover, MP leading to cell cycle arrest at G2/M phase, which subsequently activates caspase-3, -8, -9 and PARP to induce cell apoptosis. Meanwhile, we also demonstrate that MP induces a robust autophagy in OSCC cells. The results indicate cathepsin S (CTSS) is involved in MP-induced apoptosis and autophagy by modulation of p38 MAPK and JNK1/2 pathways. These findings may provide rationale to combine MP with CTSS blockade for the effective treatment of OSCC.
format Online
Article
Text
id pubmed-5361207
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53612072017-03-24 Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways Hsieh, Ming-Ju Lin, Chiao-Wen Chen, Mu-Kuan Chien, Su-Yu Lo, Yu-Sheng Chuang, Yi-Ching Hsi, Yi-Ting Lin, Chia-Chieh Chen, Jui-Chieh Yang, Shun-Fa Sci Rep Article Oral cancer is one of the most common cancers in the world. Approximately 90% of oral cancers are subtyped to oral squamous cell carcinoma (OSCC). Despite advances in diagnostic techniques and improvement in treatment modalities, the prognosis remains poor. Therefore, an effective chemotherapy mechanism that enhances tumor sensitivity to chemotherapeutics is urgently needed. Methyl protodioscin (MP) is a furostanol bisglycoside with a wide range of beneficial effects, including anti-inflammatory and anti-cancer properties. The aim of the present study was to determine the antitumor activity of MP on OSCC and its underlying mechanisms. Our results show that treatment of OSCC cells with MP potently inhibited cell viability. Moreover, MP leading to cell cycle arrest at G2/M phase, which subsequently activates caspase-3, -8, -9 and PARP to induce cell apoptosis. Meanwhile, we also demonstrate that MP induces a robust autophagy in OSCC cells. The results indicate cathepsin S (CTSS) is involved in MP-induced apoptosis and autophagy by modulation of p38 MAPK and JNK1/2 pathways. These findings may provide rationale to combine MP with CTSS blockade for the effective treatment of OSCC. Nature Publishing Group 2017-03-22 /pmc/articles/PMC5361207/ /pubmed/28327651 http://dx.doi.org/10.1038/srep45039 Text en Copyright © 2017, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Article
Hsieh, Ming-Ju
Lin, Chiao-Wen
Chen, Mu-Kuan
Chien, Su-Yu
Lo, Yu-Sheng
Chuang, Yi-Ching
Hsi, Yi-Ting
Lin, Chia-Chieh
Chen, Jui-Chieh
Yang, Shun-Fa
Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways
title Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways
title_full Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways
title_fullStr Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways
title_full_unstemmed Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways
title_short Inhibition of cathepsin S confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 MAPK/JNK signaling pathways
title_sort inhibition of cathepsin s confers sensitivity to methyl protodioscin in oral cancer cells via activation of p38 mapk/jnk signaling pathways
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361207/
https://www.ncbi.nlm.nih.gov/pubmed/28327651
http://dx.doi.org/10.1038/srep45039
work_keys_str_mv AT hsiehmingju inhibitionofcathepsinsconferssensitivitytomethylprotodioscininoralcancercellsviaactivationofp38mapkjnksignalingpathways
AT linchiaowen inhibitionofcathepsinsconferssensitivitytomethylprotodioscininoralcancercellsviaactivationofp38mapkjnksignalingpathways
AT chenmukuan inhibitionofcathepsinsconferssensitivitytomethylprotodioscininoralcancercellsviaactivationofp38mapkjnksignalingpathways
AT chiensuyu inhibitionofcathepsinsconferssensitivitytomethylprotodioscininoralcancercellsviaactivationofp38mapkjnksignalingpathways
AT loyusheng inhibitionofcathepsinsconferssensitivitytomethylprotodioscininoralcancercellsviaactivationofp38mapkjnksignalingpathways
AT chuangyiching inhibitionofcathepsinsconferssensitivitytomethylprotodioscininoralcancercellsviaactivationofp38mapkjnksignalingpathways
AT hsiyiting inhibitionofcathepsinsconferssensitivitytomethylprotodioscininoralcancercellsviaactivationofp38mapkjnksignalingpathways
AT linchiachieh inhibitionofcathepsinsconferssensitivitytomethylprotodioscininoralcancercellsviaactivationofp38mapkjnksignalingpathways
AT chenjuichieh inhibitionofcathepsinsconferssensitivitytomethylprotodioscininoralcancercellsviaactivationofp38mapkjnksignalingpathways
AT yangshunfa inhibitionofcathepsinsconferssensitivitytomethylprotodioscininoralcancercellsviaactivationofp38mapkjnksignalingpathways